To study the efficacy of pharmacological LPAR antagonists AM095 and Ki16425, we diluted the concentration of LPA to 10% (500 μM LPA in the stock tube) and added a carrier protein, 0.01% BSA, to the LPA and drug solutions, as BSA increases the solubility and bioavailability of LPA, Ki16425, and AM095 in solution (6). This LPA formulation was used for all LPAR inhibitor experiments, including Fig. 4F and fig. S7. Mice were pretreated with an intracranial injection of a 2.5-μl solution containing AM095 (1 mg/kg) (4 mM; HY-16029, MedChem), Ki16425 (1 mg/kg) (4 mM; 355025-24-0, Cayman Chemical), or vehicle (PBS with 0.01% BSA and 5% dimethyl sulfoxide) 15 min before injection at the same location with 5 μl of 18:1 LPA in PBS with 0.01% BSA.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.